Esperion Therapeutics | ESPR - Equity Capital And Reserves


Esperion Therapeutics reported $-307.93M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Amarin USD 449.41M 9.87M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cipla INR 344.32B 15.13B Mar/2026
CSL USD 18.66B 2.75B Dec/2025
Cytokinetics USD -826.57M 166.94M Mar/2026
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
Geron USD 229.11M 3.24M Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Moderna USD 7.41B 1.24B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Sanofi EUR 72.81B 1.1B Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025